4//SEC Filing
Longitude Capital Partners III, LLC 4
Accession 0000899243-20-020572
CIK 0001693011other
Filed
Jul 27, 8:00 PM ET
Accepted
Jul 28, 6:20 PM ET
Size
19.1 KB
Accession
0000899243-20-020572
Insider Transaction Report
Form 4
Longitude Capital Partners III, LLC
10% Owner
Transactions
- Conversion
Common Stock
2020-07-28+187,154→ 2,194,379 total(indirect: By Longitude Venture Partners III, L.P.) - Conversion
Series A Convertible Preferred Stock
2020-07-28−15,000,000→ 0 total(indirect: By Longitude Venture Partners III, L.P.)→ Common Stock (2,007,225 underlying) - Conversion
Common Stock
2020-07-28+2,007,225→ 2,007,225 total(indirect: By Longitude Venture Partners III, L.P.) - Purchase
Common Stock
2020-07-28$16.00/sh+625,000$10,000,000→ 2,819,379 total(indirect: By Longitude Venture Partners III, L.P.) - Conversion
Series A-2 Convertible Preferred Stock
2020-07-28−1,398,600→ 0 total(indirect: By Longitude Venture Partners III, L.P.)→ Common Stock (187,154 underlying)
Footnotes (3)
- [F1]On July 28, 2020, the Series A Convertible Preferred Stock automatically converted into Common Stock on a 7.4730-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
- [F2]These shares are held by Longitude Venture Partners III, L.P ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting and dispositive power over the shares held by LVP III. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP III and may be deemed to share voting and dispositive power with respect to the shares held by LVP III. Each of LCP III, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
- [F3]On July 28, 2020, the Series A-2 Convertible Preferred Stock automatically converted into Common Stock on a 7.4730-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
Documents
Issuer
Inozyme Pharma, Inc.
CIK 0001693011
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001713663
Filing Metadata
- Form type
- 4
- Filed
- Jul 27, 8:00 PM ET
- Accepted
- Jul 28, 6:20 PM ET
- Size
- 19.1 KB